Search

Search Constraints

You searched for: Author/Creator Alexander, James L

Search Results

2. Clinical outcomes of patients with corticosteroid refractory immune checkpoint inhibitor-induced enterocolitis treated with infliximab. Issue 7 (7th July 2021)

3. COVID-19 vaccine-induced antibody and T-cell responses in immunosuppressed patients with inflammatory bowel disease after the third vaccine dose (VIP): a multicentre, prospective, case-control study. (November 2022)

4. COVID-19 vaccine-induced antibody responses in immunosuppressed patients with inflammatory bowel disease (VIP): a multicentre, prospective, case-control study. (April 2022)

5. Inflammatory Bowel Disease Outcomes Following Fecal Microbiota Transplantation for Recurrent C. difficile Infection. Issue 9 (19th August 2021)

6. Inflammatory Bowel Disease Outcomes Following Fecal Microbiota Transplantation for Recurrent C. difficile Infection. Issue 9 (6th November 2020)

7. International Cancer Microbiome Consortium consensus statement on the role of the human microbiome in carcinogenesis. Issue 9 (15th May 2019)

8. Neutralising antibody potency against SARS-CoV-2 wild-type and omicron BA.1 and BA.4/5 variants in patients with inflammatory bowel disease treated with infliximab and vedolizumab after three doses of COVID-19 vaccine (CLARITY IBD): an analysis of a prospective multicentre cohort study. (February 2023)

9. Oral beclomethasone dipropionate is an effective treatment for immune checkpoint inhibitor induced colitis. Issue 9 (16th September 2022)